<DOC>
	<DOCNO>NCT02776644</DOCNO>
	<brief_summary>The clinical outcome advance / metastatic renal cell carcinoma change since target therapy widely apply . This study retrospectively analyse clinical outcome advance renal cell carcinoma capture Taiwan National Health Insurance Research Database .</brief_summary>
	<brief_title>Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan</brief_title>
	<detailed_description>Targeted therapy agent significantly change clinical outcome advance / metastatic renal cell carcinoma . However , dose pattern vary might result impact duration treatment . In Taiwan , National Health Insurance system coverage 90 % population thus serve appropriate database analysis Taiwanese advance renal cell carcinoma . This study retrospectively analyse clinical outcome advance renal cell carcinoma capture Taiwan National Health Insurance Research Database .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>advanced/metastatic renal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>sunitinib , pazopanib</keyword>
	<keyword>temsirolimus</keyword>
	<keyword>sorafenib</keyword>
	<keyword>everolimus</keyword>
	<keyword>interferon alpha</keyword>
	<keyword>interleukin 2</keyword>
</DOC>